Extended Dose Ipilimumab With a Peptide Vaccine: Immune Correlates Associated With Clinical Benefit in Patients With Resected High-Risk Stage IIIc/IV Melanoma

Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-10-2463
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

High-Dose Glucocorticoids for the Treatment of Ipilimumab-Induced Hypophysitis Is Associated With Reduced Survival in Patients With Melanoma

Cancer
Cancer ResearchOncology
2018English

Vaccine-Specific Immune Responses Correlate With Clinical Benefit

Cancer Discovery
Oncology
2012English

Fatal Myocarditis and Rhabdomyositis in a Patient With Stage IV Melanoma Treated With Combined Ipilimumab and Nivolumab

Current Oncology
Oncology
2019English

Antibody Response to Melanoma Helper-Peptide Vaccine Correlates With Survival

Journal for ImmunoTherapy of Cancer
OncologyMolecular MedicinePharmacologyCancer ResearchAllergyImmunology
2013English

Q-TWiST Analysis Comparing Ipilimumab/Dacarbazine vs Placebo/Dacarbazine for Patients With Stage III/IV Melanoma

British Journal of Cancer
Cancer ResearchOncology
2013English

Bevacizumab Plus Ipilimumab in Patients With Metastatic Melanoma

Cancer immunology research
Cancer ResearchImmunology
2014English

Association of First-In-Class Immune Checkpoint Inhibition and Targeted Therapy With Survival in Patients With Stage IV Melanoma

JAMA Oncology
Cancer ResearchOncology
2018English

Prolonged Benefit From Ipilimumab Correlates With Improved Outcomes From Subsequent Pembrolizumab

Cancer immunology research
Cancer ResearchImmunology
2016English

Adjuvant Ipilimumab in High-Risk Uveal Melanoma

Cancers
Cancer ResearchOncology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy